Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio
Background Subcutaneous immunotherapy (SCIT) traditionally includes an updosing phase injecting increasing doses of allergen over a period of several weeks, followed by a maintenance phase. To establish shorter and more convenient updosing schedules, a fast updosed immunologically enhanced SCIT form...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2012
|
| In: |
Allergy
Year: 2012, Jahrgang: 67, Heft: 5, Pages: 630-637 |
| ISSN: | 1398-9995 |
| DOI: | 10.1111/j.1398-9995.2012.02801.x |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1111/j.1398-9995.2012.02801.x Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1398-9995.2012.02801.x 
|
| Verfasserangaben: | O. Pfaar, K. Jung, H. Wolf, E. Decot, J. Kleine‐Tebbe, L. Klimek & E. Wüstenberg |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576819264 | ||
| 003 | DE-627 | ||
| 005 | 20220814173557.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180625s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1398-9995.2012.02801.x |2 doi | |
| 035 | |a (DE-627)1576819264 | ||
| 035 | |a (DE-576)506819264 | ||
| 035 | |a (DE-599)BSZ506819264 | ||
| 035 | |a (OCoLC)1341012003 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pfaar, Oliver |d 1972- |e VerfasserIn |0 (DE-588)12385900X |0 (DE-627)706454049 |0 (DE-576)293913099 |4 aut | |
| 245 | 1 | 0 | |a Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio |c O. Pfaar, K. Jung, H. Wolf, E. Decot, J. Kleine‐Tebbe, L. Klimek & E. Wüstenberg |
| 264 | 1 | |c 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Issue online: 11 April 2012 | ||
| 500 | |a Gesehen am 25.06.2018 | ||
| 520 | |a Background Subcutaneous immunotherapy (SCIT) traditionally includes an updosing phase injecting increasing doses of allergen over a period of several weeks, followed by a maintenance phase. To establish shorter and more convenient updosing schedules, a fast updosed immunologically enhanced SCIT formulation has been developed by optimizing the allergen/adjuvant (aluminium hydroxide) ratio. Methods In a randomized, controlled, parallel-group trial, patients with grass pollen induced rhinoconjunctivitis with/without asthma were treated with an immunologically enhanced SCIT formulation (AVANZ, ALK, Denmark). The trial included updosing with five injections (300, 600, 3000, 6000 and 15 000 SQ+) injected either in weekly interval (Group 1) or in 3-4 days interval (Group 2) followed by two maintenance injections (15 000 SQ+), approximately 10 weeks treatment. The immunological effects (primary endpoint) and tolerability (secondary endpoint) of the updosing schedules were evaluated. Results Four hundred patients were treated (Group 1: 201, Group 2: 199). In both groups, an immunological response with statistically significant increases in levels of IgE-blocking factor, IgG4 and IgE (P < 0.001), was induced from baseline to end of trial. Most frequently reported adverse events were local injection site reactions such as injection site swellings (Group 1: 30% of patients, Group 2: 41% of patients). Other frequently reported adverse events included systemic reactions (Group 1: 21% of patients, Group 2: 33% of patients), primarily mild to moderate allergic rhinitis and urticaria. Conclusions Fast updosed immunologically enhanced SCIT with an optimized allergen/adjuvant ratio induced significant immunological effects and had an acceptable safety profile. Clinical efficacy will be investigated in future clinical trials. | ||
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a short updosing | |
| 650 | 4 | |a subcutaneous immunotherapy | |
| 650 | 4 | |a tolerability | |
| 700 | 1 | |a Klimek, Ludger |d 1964- |e VerfasserIn |0 (DE-588)172705037 |0 (DE-627)697637476 |0 (DE-576)133562751 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Allergy |d Oxford : Wiley, 1978 |g 67(2012), 5, Seite 630-637 |h Online-Ressource |w (DE-627)320425428 |w (DE-600)2003114-2 |w (DE-576)091140153 |x 1398-9995 |7 nnas |a Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio |
| 773 | 1 | 8 | |g volume:67 |g year:2012 |g number:5 |g pages:630-637 |g extent:8 |a Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1398-9995.2012.02801.x |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1398-9995.2012.02801.x |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180625 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 172705037 |a Klimek, Ludger |m 172705037:Klimek, Ludger |d 60000 |d 62100 |e 60000PK172705037 |e 62100PK172705037 |k 0/60000/ |k 1/60000/62100/ |p 6 | ||
| 998 | |g 12385900X |a Pfaar, Oliver |m 12385900X:Pfaar, Oliver |d 60000 |d 62100 |e 60000PP12385900X |e 62100PP12385900X |k 0/60000/ |k 1/60000/62100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1576819264 |e 3013697342 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio","title":"Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio"}],"recId":"1576819264","origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"2012"}],"name":{"displayForm":["O. Pfaar, K. Jung, H. Wolf, E. Decot, J. Kleine‐Tebbe, L. Klimek & E. Wüstenberg"]},"person":[{"role":"aut","family":"Pfaar","given":"Oliver","display":"Pfaar, Oliver"},{"role":"aut","family":"Klimek","display":"Klimek, Ludger","given":"Ludger"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1398-9995"],"doi":["10.1111/(ISSN)1398-9995"],"zdb":["2003114-2"],"eki":["320425428"]},"part":{"issue":"5","extent":"8","pages":"630-637","year":"2012","volume":"67","text":"67(2012), 5, Seite 630-637"},"note":["Gesehen am 14.08.14"],"origin":[{"publisher":"Wiley ; Blackwell Munksgaard","dateIssuedDisp":"1978-","dateIssuedKey":"1978","publisherPlace":"Oxford ; Oxford"}],"title":[{"title":"Allergy","title_sort":"Allergy"}],"pubHistory":["33.1978 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320425428","disp":"Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratioAllergy","language":["eng"]}],"note":["Issue online: 11 April 2012","Gesehen am 25.06.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1111/j.1398-9995.2012.02801.x"],"eki":["1576819264"]},"physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a PFAAROLIVEIMMUNOLOGI2012 | ||